PT-141 (Bremelanotide) dosage by bodyweight
Reference dose ranges scaled across bodyweight bands, anchored to the most-cited research dose (1000 mcg @ 75 kg). Educational only, never a recommendation.
| Bodyweight band | Reference dose range | At U-100 (1 mg/mL) | Vol. on U-100 (5 mg / 2 mL) | 5× t½ elapsed |
|---|---|---|---|---|
| <60 kg / <132 lb | 623–843 mcg | 0.62–0.84 mL | 25–34 units0.25–0.34 mL | – |
| 60–75 kg / 132–165 lb | 765–1035 mcg | 0.77–1.03 mL | 31–41 units0.31–0.41 mL | – |
| 75–90 kg / 165–198 lb | 935–1265 mcg | 0.94–1.26 mL | 37–51 units0.37–0.51 mL | – |
| 90–105 kg / 198–231 lb | 1105–1495 mcg | 1.10–1.50 mL | 44–60 units0.44–0.60 mL | – |
| >105 kg / >231 lb | 1275–1725 mcg | 1.27–1.73 mL | 51–69 units0.51–0.69 mL | – |
Volume column assumes a standard 5 mg vial reconstituted with 2 mL bacteriostatic water (concentration 2.5 mg/mL); insulin units shown for a U-100 syringe. No published half-life on file for PT-141 (Bremelanotide); the elapsed-time column is hidden.
PT-141 (Bremelanotide) by goal
Read PT-141 (Bremelanotide)'s profile and dosing through a specific research-goal lens.
Dose & PK references
Selected from the PT-141 (Bremelanotide) bibliography for relevance to dosing and pharmacokinetics.
- Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options
- Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction
- PT-141: a melanocortin agonist for the treatment of sexual dysfunction
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.